NO304887B1 - Endotelin-reseptor-antagonister, anvendelse derav og farmas°ytiske preparater inneholdende dem - Google Patents

Endotelin-reseptor-antagonister, anvendelse derav og farmas°ytiske preparater inneholdende dem

Info

Publication number
NO304887B1
NO304887B1 NO941650A NO941650A NO304887B1 NO 304887 B1 NO304887 B1 NO 304887B1 NO 941650 A NO941650 A NO 941650A NO 941650 A NO941650 A NO 941650A NO 304887 B1 NO304887 B1 NO 304887B1
Authority
NO
Norway
Prior art keywords
receptor antagonists
pharmaceutical preparations
preparations containing
endothelin receptor
endothelin
Prior art date
Application number
NO941650A
Other languages
English (en)
Norwegian (no)
Other versions
NO941650L (no
NO941650D0 (no
Inventor
Russell Donovan Cousins
John Duncan Elliott
Maria Amparo Lago
Jack Dale Leber
Catherine Elizabeth Peishoff
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO941650D0 publication Critical patent/NO941650D0/no
Publication of NO941650L publication Critical patent/NO941650L/no
Publication of NO304887B1 publication Critical patent/NO304887B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO941650A 1991-11-05 1994-05-04 Endotelin-reseptor-antagonister, anvendelse derav og farmas°ytiske preparater inneholdende dem NO304887B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78787091A 1991-11-05 1991-11-05
US85419592A 1992-03-20 1992-03-20
PCT/US1992/009427 WO1993008799A1 (en) 1991-11-05 1992-10-29 Endothelin receptor antagonists

Publications (3)

Publication Number Publication Date
NO941650D0 NO941650D0 (no) 1994-05-04
NO941650L NO941650L (no) 1994-07-01
NO304887B1 true NO304887B1 (no) 1999-03-01

Family

ID=27120702

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941650A NO304887B1 (no) 1991-11-05 1994-05-04 Endotelin-reseptor-antagonister, anvendelse derav og farmas°ytiske preparater inneholdende dem

Country Status (33)

Country Link
EP (1) EP0612244B1 (de)
JP (1) JP2667294B2 (de)
KR (1) KR100342960B1 (de)
CN (2) CN1034569C (de)
AP (1) AP433A (de)
AT (1) ATE205711T1 (de)
AU (1) AU669866B2 (de)
BG (1) BG61523B1 (de)
BR (1) BR9206722A (de)
CA (1) CA2122820A1 (de)
CZ (1) CZ287406B6 (de)
DE (1) DE69232072T2 (de)
DK (1) DK0612244T3 (de)
ES (1) ES2164054T3 (de)
FI (1) FI942059A (de)
HK (1) HK1012251A1 (de)
HU (1) HUT67665A (de)
IL (1) IL103621A0 (de)
MA (1) MA22758A1 (de)
MX (1) MX9206348A (de)
MY (1) MY108579A (de)
NO (1) NO304887B1 (de)
NZ (1) NZ245000A (de)
OA (1) OA09921A (de)
PL (1) PL176250B1 (de)
PT (1) PT101038B (de)
RO (1) RO117847B1 (de)
RU (1) RU2125980C1 (de)
SI (1) SI9200297B (de)
SK (1) SK282098B6 (de)
TW (1) TW298590B (de)
UA (1) UA44686C2 (de)
WO (1) WO1993008799A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5817693A (en) * 1991-11-05 1998-10-06 Cousins; Russell Donovan Endothelin receptor antagonists
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
AU4376893A (en) * 1992-05-19 1993-12-13 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
ES2062927B1 (es) * 1992-12-17 1995-07-01 Smithkline Beecham Corp Antagonistas de los receptores de endotelina y procedimiento para su preparacion.
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
GB9307694D0 (en) 1993-04-14 1993-06-02 Smithkine Beecham Corp Novel compounds
EP0626174A3 (de) 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Verfahren und Zusammensetzung für die Prophylaxe und/oder Behandlung von Organunterfunktion.
EP0699069B9 (de) * 1993-04-27 2003-10-22 Smithkline Beecham Corporation Endothelin-rezeptor-antagonisten
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
WO1995004530A1 (en) * 1993-08-06 1995-02-16 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1995004534A1 (en) * 1993-08-06 1995-02-16 Smithkline Beecham Corporation Endothelin receptor antagonists
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5714479A (en) * 1993-08-18 1998-02-03 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
CN1049219C (zh) * 1993-08-18 2000-02-09 万有制药株式会社 具有内皮素拮抗活性的芳香杂环并环戊烯衍生物
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
RU2126418C1 (ru) * 1993-11-01 1999-02-20 Циба-Гейги Джапан Димитед Антагонисты рецепторов эндотелина
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
EP0763035A4 (de) * 1994-06-09 1997-10-01 Smithkline Beecham Corp Endothelin-rezeptor antagonisten
JPH10501812A (ja) * 1994-06-20 1998-02-17 スミスクライン・ビーチャム・コーポレイション エンドセリン受容体拮抗薬
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
EP1186603A3 (de) * 1994-08-19 2003-07-09 Abbott Laboratories Verfahren zur Herstellung von Endothelin-Antagonisten
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
WO1996020193A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation Compounds and methods
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
EP0757055B1 (de) * 1995-06-30 1999-10-27 Cerbios-Pharma S.A. Glykoside, deren zuckerfreie Abbauprodukte und Derivate derselben
DE19527568A1 (de) * 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
CA2227384A1 (en) * 1995-08-17 1997-02-27 Toshifumi Watanabe Thienopyrimidine derivatives, their production and use
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CA2236924A1 (en) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
ATE236151T1 (de) * 1995-11-08 2003-04-15 Smithkline Beecham Corp Ein verfahren zur herstellung von 3-phenyl-1- methylendioxyphenyl-indan-2-carbonsäurederivate
WO1997017341A1 (en) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation A process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives
ZA969363B (en) * 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
DE19543639A1 (de) * 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
CZ296660B6 (cs) * 1996-02-13 2006-05-17 Abbott Laboratories Benzo-1,3-dioxolyl- a benzofuranyl-substituované pyrrolidinové deriváty jako antagonisté endothelinu
CZ253698A3 (cs) * 1996-02-13 1999-03-17 Abbott Laboratories Deriváty 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-karboxylové kyseliny jako antagonisté endothelinu
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
WO1997029747A1 (en) 1996-02-20 1997-08-21 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
DE69715865T2 (de) * 1996-07-01 2003-08-07 Schering Corp., Kenilworth Muscarin-antagonisten
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US6172235B1 (en) 1996-08-09 2001-01-09 Merck & Co., Inc. Asymmetric conjugate addition reaction
JP3262805B2 (ja) * 1996-08-09 2002-03-04 メルク エンド カンパニー インコーポレーテッド 非対称性共役付加反応
WO1998006700A1 (en) * 1996-08-09 1998-02-19 Merck & Co., Inc. Stereoselective deoxygenation reaction
US6218427B1 (en) 1996-08-27 2001-04-17 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5998625A (en) * 1997-01-14 1999-12-07 Merck & Co., Inc. Asymmetric conjugate addition reaction using a chiral additive
TW432028B (en) * 1997-01-14 2001-05-01 Merck & Co Inc Asymmetric conjugate addition reaction using a chiral additive
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6013674A (en) * 1997-06-02 2000-01-11 Eli Lilly And Company Cell adhesion inhibitors
JP4058507B2 (ja) 1997-07-10 2008-03-12 国立大学法人 東京医科歯科大学 ４，５−ジヒドロ−［１Ｈ］−ベンズ［ｇ］インダゾール−３−カルボン酸誘導体
US6022972A (en) * 1997-08-08 2000-02-08 Merck & Co., Inc. Pyridine propanoic acid derivatives
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1999037639A1 (en) * 1998-01-21 1999-07-29 Banyu Pharmaceutical Co., Ltd. Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
IL144708A0 (en) 1999-03-19 2002-06-30 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamide derivatives
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
DE60012508T2 (de) * 1999-05-26 2005-06-23 Warner-Lambert Company Llc Aminosäuren mit polycyclischer struktur als pharmaka
AU5667900A (en) 1999-06-30 2001-01-22 Prescient Neuropharma Inc. 2-aminoindane analogs
PL197782B1 (pl) 1999-12-31 2008-04-30 Encysive Pharmaceuticals Inc Sulfonoamidy, środek farmaceutyczny i zastosowanie sulfonoamidów
NZ530051A (en) 2001-06-12 2006-12-22 Wellstat Therapeutics Corp Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders
US7767683B2 (en) 2003-08-18 2010-08-03 H. Lundbeck A/S Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament
KR100595963B1 (ko) * 2004-04-13 2006-07-05 한국화학연구원 인덴 유도체 및 이의 제조방법
WO2006066748A1 (en) 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof as 5-ht antagonists
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
WO2008103345A2 (en) 2007-02-19 2008-08-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
CN103108638B (zh) 2010-04-15 2016-11-09 海洋聚合物技术公司 聚-n-乙酰葡萄糖胺纳米纤维的抗菌应用
WO2012142581A1 (en) 2011-04-15 2012-10-18 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acety glucosamine nanofibers
CN110343038B (zh) * 2018-04-02 2022-03-15 暨南大学 一种宝乐果单体、提取物及其制备方法和应用
EP4367112A1 (de) 2021-07-09 2024-05-15 Plexium, Inc. Arylverbindungen und pharmazeutische zusammensetzungen zur modulierung von ikzf2
WO2024005578A1 (ko) * 2022-06-29 2024-01-04 아밀로이드솔루션 주식회사 신규 인덴온 유도체 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642785A (en) * 1969-08-11 1972-02-15 Merck & Co Inc Indenyl-3-aliphatic amines
US3737455A (en) * 1971-01-21 1973-06-05 Merck & Co Inc Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof
US4224341A (en) * 1976-01-12 1980-09-23 Lipha, Lyonnaise Industrielle Pharmaceutique 5-Substituted indan-2 carboxylic acid and functional derivatives
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
JPS61197557A (ja) * 1985-02-27 1986-09-01 Sankyo Co Ltd インダン誘導体およびその製法
IT1190371B (it) * 1985-06-19 1988-02-16 Zambon Spa Processo per la preparazione dell'acido cis-5-fluoro-2-metil-1-(4-metiltiobenziliden)-indenil-3-acetico

Also Published As

Publication number Publication date
MX9206348A (es) 1994-06-30
UA44686C2 (uk) 2002-03-15
MA22758A1 (fr) 1993-10-01
TW298590B (de) 1997-02-21
SI9200297B (sl) 2003-02-28
AU669866B2 (en) 1996-06-27
IL103621A0 (en) 1993-04-04
DE69232072T2 (de) 2002-06-20
ATE205711T1 (de) 2001-10-15
ES2164054T3 (es) 2002-02-16
PT101038A (pt) 1994-02-28
AU3125993A (en) 1993-06-07
MY108579A (en) 1996-10-31
JPH07501322A (ja) 1995-02-09
KR100342960B1 (de) 2003-02-11
NO941650L (no) 1994-07-01
AP9200440A0 (en) 1993-01-31
NO941650D0 (no) 1994-05-04
NZ245000A (en) 1996-05-28
OA09921A (en) 1994-08-15
CN1034569C (zh) 1997-04-16
PL176250B1 (pl) 1999-05-31
CN1145223A (zh) 1997-03-19
JP2667294B2 (ja) 1997-10-27
CZ287406B6 (cs) 2000-11-15
BG61523B1 (en) 1997-11-28
BG98752A (bg) 1995-05-31
AP433A (en) 1995-11-17
PT101038B (pt) 1999-07-30
WO1993008799A1 (en) 1993-05-13
EP0612244A1 (de) 1994-08-31
DK0612244T3 (da) 2002-01-14
RO117847B1 (ro) 2002-08-30
HU9401319D0 (en) 1994-08-29
FI942059A0 (fi) 1994-05-04
CZ110994A3 (en) 1995-01-18
HUT67665A (en) 1995-04-28
FI942059A (fi) 1994-07-04
SK52194A3 (en) 1995-03-08
EP0612244A4 (de) 1995-05-17
BR9206722A (pt) 1995-07-18
CN1073161A (zh) 1993-06-16
SI9200297A (en) 1993-06-30
RU2125980C1 (ru) 1999-02-10
SK282098B6 (sk) 2001-11-06
EP0612244B1 (de) 2001-09-19
HK1012251A1 (en) 1999-07-30
CA2122820A1 (en) 1993-05-13
DE69232072D1 (de) 2001-10-25

Similar Documents

Publication Publication Date Title
NO304887B1 (no) Endotelin-reseptor-antagonister, anvendelse derav og farmas°ytiske preparater inneholdende dem
NO308298B1 (no) Substituerte kinazolinderivater, anvendelse derav og farmasøytiske preparater inneholdende dem
NO305952B1 (no) 1,5-benzodiazepinderivater, anvendelse derav og farmasoeytiske preparater
NO921012L (no) Farmasoeytiske preparater og deres anvendelse
EE9400455A (et) Peptiidi derivaadid, nende valmistamise protsess, neid sisaldavad ravimpreparaadid ja nende kasutamine
NO305317B1 (no) Sulfonamid-endotelin-antagonister anvendelser derav og farmas°ytisk preparat
DK1023900T3 (da) Farmaceutisk præparat indeholdende S-nitroso-lipoproteiner og anvendelse deraf
NO943511D0 (no) Farmasöytiske preparater og anvendelse derav
NO965103L (no) Bicykliske aromatiske forbindelser, anvendelse derav, og farmasöytiske og kosmetiske preparater
NO902658D0 (no) N-fenylpyrazolderivater, preparater og anvendelse derav.
NO942835L (no) 1-benzensulfonyl-1,3-dihydro-2H-benzimidazol-2-on-derivater, fremstilling derav og farmasöytiske blandinger som inneholder dem
NO894228D0 (no) Tienopyridiner, fremstilling, mellomprodukter og farmasoeytiske preparater.
NO308533B1 (no) Heteroarylaminer, anvendelse derav og farmasøytisk preparat
NO985368D0 (no) Substituerte imidazolidinderivater, deres fremstilling, deres anvendelse og farmas°ytiske preparater inneholdende forbindelsene
NO303446B1 (no) Nye 2-sakkarinylmetylaryl- og -aryloksyacetater, preparater og anvendelse derav
NO984309D0 (no) Nye imidazolidinderivater, deres fremstilling, deres anvendelse og farmas°ytiske preparater inneholdende disse
DK127691D0 (da) Mucoadhaesivt baerestof og farmaceutisk doseringsform indeholdende dette baerestof
EP0672052A1 (de) Tachyquinin antagonisten, ihre herstellung und ihre verwendung in pharmazeutischen formulierungen.
NO931364L (no) Tachykinin reseptorantagonister, isokinoloner og deres fremstilling
DK578589D0 (da) Farmaceutisk praeparat indeholdende labdanterpenoidderivater og pyrimido(6,1-a)isoquinolin-4-onderivater, dets fremstilling og anvendelse
NO930390D0 (no) Nye hetaryloxy-beta-carboliner, deres fremstilling og anvendelse i legemidler
NO923293L (no) Farmasoeytiske preparater inneholdende bradykininantagonister til lokal anvendelse i nese og oeye
NO923720L (no) Tienocyklopentanonoksimetere, fremstilling derav og farmasoeytiske blandinger som inneholder dem
GB2253851B (en) Pyridine derivatives,their preparation and pharmaceutical use
NO179907C (no) Benzokinoksaliner og farmasöytiske preparater inneholdende de samme

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees